Mixed results for Moderna mRNA flu vaccine trial
Washington (AFP) - US biotech company Moderna said Thursday it had mixed results from a large-scale trial of its mRNA flu shot, based on the same technology used in its successful Covid-19 vaccine. Moderna's experimental mRNA-1010 flu shot is "quadrivalent," meaning it targets four strains of flu: A/H1N1, A/H3N2, B/Yamagata and B/Victoria -- selected based on recommendations by the World Health Organization (WHO). The Massachusetts-based company said that its flu shot generated an immune response against influenza A strains that was equal or superior to that of already licensed vaccines. Howev...